Mark Foundation for Cancer Research
Investments
7Partners & Customers
4About Mark Foundation for Cancer Research
Mark Foundation for Cancer Research is dedicated to accelerating cures for cancer by integrating discoveries in biology with technology. It funds a portfolio of research carried out by individual investigators, multi-investigator teams, and inter-institutional collaborations. It maintains a nimble, high-impact approach to funding that encompasses grants for basic and translational research, as well as venture philanthropy investment in companies that bridge the gap between bench and bedside.
Want to inform investors similar toMark Foundation for Cancer Researchabout your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
LatestMark Foundation for Cancer ResearchNews
Feb 23, 2023
分享这篇文章提供的新闻分享这门艺术icle -Over 100 ASPIRE awards have been granted across 12 countries and 58 institutions since the program launched in 2018 NEW YORK, Feb. 23, 2023 /PRNewswire/ -- The Mark Foundation for Cancer Research announced twelve outstanding research projects to receive its latest round of ASPIRE awards . Grantees from top academic institutions in Germany, Israel, Netherlands, Spain, and USA were awarded more than $4 million for projects that either aim to answer key feasibility and proof-of-concept questions in an accelerated time frame or seek to build on such demonstrated feasibility / proof-of-concept with a longer duration ASPIRE II Award. Ten ASPIRE awards and two ASPIRE II awards were granted. "The Mark Foundation ASPIRE awards support innovative ideas worldwide that have the potential to solve high-impact problems in cancer research. The high-risk nature of these projects, often based on new ideas that have not generated extensive preliminary data, tends to place them outside the scope of other funding opportunities," noted Ryan Schoenfeld, PhD, Chief Executive Officer, The Mark Foundation. "These latest grants utilize innovative technologies to enable research aimed at solving critical challenges across multiple cancer types including breast cancer, lung cancer, melanoma, and prostate cancer." "Launched in 2018, The Mark Foundation ASPIRE program has provided more than 100 grants totaling over $42 million across 12 countries and 58 institutions," added Raymond N. DuBois, MD, PhD, Executive Chairman, The Mark Foundation. "We are committed to increasing our global commitment to accelerate the pace of scientific discovery and the development of new cancer therapies and diagnostics." The Mark Foundation's new class of ASPIRE awards is listed below. For more detailed information on each project, titles link to the corresponding project pages on The Mark Foundation website. David Bilder, PhD, University of California, Berkeley About The Mark Foundation for Cancer Research The Mark Foundation for Cancer Research actively partners with scientists, research institutions, and philanthropic organizations around the world to accelerate research that will transform the prevention, diagnosis, and treatment of cancer. Since 2017, The Mark Foundation has awarded more than $185 million in grants to enable innovative basic, translational, and clinical cancer research, including drug discovery. In 2022, The Mark Foundation received an additional $500 million commitment to fund cutting-edge cancer research in its first decade. The Mark Foundation also has a robust and growing portfolio of investments in oncology companies developing novel therapeutics and diagnostics. Through its research and venture arms, The Mark Foundation supports projects throughout their life cycle to ensure their highest chance of success in impacting the lives of patients with breakthroughs in cancer care. To learn more please visit www.TheMarkFoundation.org . Media Contact:
Mark Foundation for Cancer Research Investments
7 Investments
Mark Foundation for Cancer Research has made7 investments.Their latest investment was inVicinitas Therapeuticsas part of theirSeries AonJuly 7, 2022.
Mark Foundation for Cancer Research Investments Activity
Date |
Round |
Company |
Amount |
New? |
Co-Investors |
Sources |
---|---|---|---|---|---|---|
7/28/2022 |
Series A |
Vicinitas Therapeutics |
$65M |
Yes |
3 |
|
8/18/2021 |
Series B |
|||||
5/18/2021 |
Series A |
|||||
4/15/2021 |
Series B |
|||||
6/8/2020 |
Series A |
Date |
7/28/2022 |
8/18/2021 |
5/18/2021 |
4/15/2021 |
6/8/2020 |
---|---|---|---|---|---|
Round |
Series A |
Series B |
Series A |
Series B |
Series A |
Company |
Vicinitas Therapeutics |
||||
Amount |
$65M |
||||
New? |
Yes |
||||
Co-Investors |
|||||
Sources |
3 |
Mark Foundation for Cancer Research Partners & Customers
4 Partners and customers
Mark Foundation for Cancer Research has4 strategic partners and customers.Mark Foundation for Cancer Research recently partnered withProstate Cancer ResearchonJuly 7, 2021.
Date |
Type |
Business Partner |
Country |
News Snippet |
Sources |
---|---|---|---|---|---|
7/1/2021 |
Partner |
|
1 |
||
3/26/2019 |
Partner |
||||
1/23/2019 |
Partner |
||||
5/22/2018 |
Partner |
Date |
7/1/2021 |
3/26/2019 |
1/23/2019 |
5/22/2018 |
---|---|---|---|---|
Type |
Partner |
Partner |
Partner |
Partner |
Business Partner |
||||
Country |
|
|||
News Snippet |
||||
Sources |
1 |
Mark Foundation for Cancer ResearchTeam
1 Team Member
Mark Foundation for Cancer Researchhas1 team member,includingformer Chief Medical Officer, Steven H. Bernstein.
Name |
Work History |
Title |
Status |
---|---|---|---|
Steven H. Bernstein |
Turnstone Biologics,Bristol-Myers Squibb,University of Rochester Medical Center,andRoswell Park Cancer Institute |
Chief Medical Officer |
Former |
Name |
Steven H. Bernstein |
---|---|
Work History |
Turnstone Biologics,Bristol-Myers Squibb,University of Rochester Medical Center,andRoswell Park Cancer Institute |
Title |
Chief Medical Officer |
Status |
Former |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.